Trial Profile
A Phase I Clinical Study of BBI608 in Adult Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary)
- Indications Anal cancer; Carcinoma; Colorectal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 17 Jan 2021 Results assessing food effects on napabucasin pharmacokinetics in two studies JapicCTI-205447; NCT01775423, presented at the 2021 Gastrointestinal Cancers Symposium.
- 30 Sep 2019 Status changed from active, no longer recruiting to completed.
- 25 Mar 2019 Planned End Date changed from 30 Apr 2019 to 1 Oct 2019.